Zinacef

Zinacef

cefuroxime

Manufacturer:

GlaxoSmithKline

Distributor:

Zuellig
Concise Prescribing Info
Contents
Cefuroxime (tab: axetil; inj: Na)
Indications/Uses
Upper & lower resp, genito-urinary tract, ENT, skin & soft tissue, bone & joint, O & G infections, gonorrhea & other infections including septicemia, meningitis & peritonitis. Prophylaxis against infections in abdominal, pelvic, orthopedic, cardiac, pulmonary, esophageal & vascular surgery where there is increased risk from infections. Tab: Treatment & prevention of early & late Lyme disease in adult & childn ≥3 mth.
Dosage/Direction for Use
Tab Adult Most infections, UTI, mild to moderate lower resp tract infections (eg, bronchitis), pyelonephritis 250 mg bid. More severe lower resp tract infections or pneumonia (if suspected) 500 mg bid. Uncomplicated gonorrhea 1 g as single dose. Adult & childn >12 yr Lyme disease 500 mg bid for 14 days. Sequential therapy: Pneumonia 1.5 g tid or bid (IV or IM) for 48-72 hr, followed by 500 mg bid for 7-10 days. Acute exacerbations of chronic bronchitis 750 mg tid or bid (IV or IM) for 48-72 hr, followed by 500 mg tid or bid for 5-10 days. Childn Most infections 125 mg bid, max: 250 mg daily. ≥2 yr Otitis media or more severe infections 250 mg bid, max: 500 mg daily. 3 mth-12 yr Lyme disease 250 mg bid, max 500 mg daily for 14 days. Renal impairment CrCl ≥30 mL/min 125-500 mg bid; 10-29 mL/min Standard individual dose every 24 hr; <10 mL/min Standard individual dose every 48 hr. Inj Adult 750 mg tid by IM or IV. More severe infections: 1.5 g tid IV. May be increased 6 hrly if required; total daily dose 3-6 g. Infant & childn 30-100 mg/kg/day 3-4 divided doses. 60 mg/kg/day is appropriate for most infections. Neonate 30-100 mg/kg/day as 2-3 divided doses. Gonorrhea 1.5 g as single dose, given as 2 x 750 mg IM at different sites. Meningitis Adult 3 g IV 8 hrly. Infant & childn 150-250 mg/kg/day in 3-4 divided doses. Neonate 100 mg/kg/day IV. Surgical prophylaxis 1.5 g IV w/ induction of anesth for abdominal, pelvic & orthopedic operations; may be supplemented w/ two 750 mg IM doses 8 & 16 hr later. Cardiac, pulmonary, esophageal & vascular operations 1.5 g IV w/ induction of anesth continuing w/ 750 mg IM tid for a further 24-48 hr. Total joint replacement 1.5 g cefuroxime may be mixed dry w/ each pack of methyl methacrylate cement polymer before adding the liqd monomer. Sequential therapy: Pneumonia 1.5 g bid or tid by IM or IV for 48-72 hr, followed by 500 mg bid orally for 7-10 days. Acute exacerbations of chronic bronchitis 750 mg bid or tid by IM or IV for 48-72 hr, followed by 500 mg bid orally for 5-10 days. Renal impairment (CrCl 10-29 mL/min) 750 mg every 24 hr. Severe renal impairment (CrCl ≤10 mL/min) 750 mg every 48 hr. Patient on hemodialysis 750 mg IV or IM at the end of each dialysis. Patient w/ renal failure on continuous arteriovenous hemodialysis or high flux hemofiltration 750 mg bid.
Administration
Should be taken with food: Take after meals for better absorption. Do not crush.
Contraindications
Special Precautions
Concurrent treatment w/ potent diuretics eg, furosemide or aminoglycosides. Renal impairment. Prolonged use may result to overgrowth of other nonsusceptible organisms. Pseudomembranous colitis. Slight interference w/ copper reduction methods (Benedict's, Fehling's, Clinitest). Pregnancy & lactation. Tab: May impair ability to drive or operate machinery.
Adverse Reactions
Eosinophilia; transient increase in hepatic enzyme levels. Tab: Overgrowth of Candida; headache, dizziness; diarrhea, nausea, abdominal pain. Inj: Neutropenia; inj site reactions eg, pain & thrombophlebitis.
Drug Interactions
Tab: Lower bioavailability of drugs which reduce gastric acidity. Lower estrogen reabsorption & reduced efficacy of OCs.
MIMS Class
Cephalosporins
ATC Classification
J01DC02 - cefuroxime ; Belongs to the class of second-generation cephalosporins. Used in the systemic treatment of infections.
Presentation/Packing
Form
Zinacef inj 750 mg
Packing/Price
1's
Form
Zinacef tab 500 mg
Packing/Price
50's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in